Home > Formulary : Adult > Recent Decisions > 2022 >
Decisions 13th September 2022
Decisions 13th September 2022
At the meeting on the 13th September, the following decisions were agreed
New Drug Requests
Approved
Perflutren (Luminity) (TLS Red)
-
For ultrasound contrast-enhancing agent for use in adult patients as an alternative to SonoVue
Tretinoin 0.025% / Clindamycin 1% Gel (TLS Green)
-
For acne
-
Tretinoin/Erythromycin removed from the Formulary
Synalar® (fluocinolone ointment 0.025%) ointment/cream (TLS Blue)
-
For severe inflammatory skin disorders such as eczema and psoriasis
-
Synalar gel (already on formulary) TLS changed from green to blue inline with other formulations of Synalar.
Not Approved
Melatonin (Adults)
-
Off-label use in patients with dementia experiencing circadian sleep disorders, in whom conventional sedation is considered too risky
Decision Pending
Melatonin (Adults and Paediatrics)
-
Off-label use for sleep disorder in adult and paediatric patients with any of:
-
Attention Deficit Hyperactivity Disorder (ADHD)
-
Autism Spectrum Disorder (ASD)
-
Learning Disabilities (LD)
-
Other Formulary Decisions
-
Roxadustat for treating symptomatic anaemia in chronic kidney disease as per NICE TA807 added to Formulary as TLS Red in line with updated NICE TA resource impact report.
-
Alprostadil listing updated to include all available brands (Caverject and Viridal Duo) to support with recent supply problems. The lowest acquisition cost should be prescribed and brands should not be changed without appropriate patient counselling.
-
Sip feed chapter review – proposed amendments approved